RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for inflammatory and immunological diseases and cancer. The company’s work centers on drug candidates intended for use in areas such as immunology, inflammation, and oncology, with development activities conducted through its corporate research and clinical organization in the United States.

4.87

4.87

— RAPT Therapeutics, Inc.
%
Inflammation and immunology programs50% Drug discovery and development efforts targeting inflammatory and immune-mediated diseases.
Oncology programs35% Therapeutic candidates and research programs aimed at cancer indications.
Preclinical research15% Early-stage discovery, screening, and translational work supporting the pipeline.

RAPT does not currently sell commercial products; its near-term counterparties are primarily clinical investigators,...

  • Clinical development partnersprimary

    CROs, trial sites, and manufacturers that support testing and supply of drug candidates.

  • Potential strategic partnersprimary

    Biopharma companies that may license, co-develop, or commercialize candidates.

  • Healthcare providerssecondary

    Physicians and hospitals that would prescribe or administer approved therapies.

  • Third-party payorssecondary

    Insurers and government payors that determine coverage and reimbursement.

RAPT is headquartered and operates in the United States, where its research, clinical development, and corporate...

  • •United States is the core operating base and reporting jurisdiction
  • •Clinical trials may involve sites outside the U.S. through partners
  • •Manufacturing and supply chains can span multiple countries
  • •Regulatory exposure includes FDA and potentially foreign agencies

RAPT’s strategy is to advance its pipeline through preclinical and clinical development, using external partners where...

01
Advance pipeline candidatesshort-term

Clinical and preclinical progress is the main value driver for a therapeutics company with no product revenue.

02
Secure development and commercialization partnersmedium-term

The company lacks internal sales and distribution capabilities and may need third parties to bring products to market.

03
Maintain funding runwayshort-term

Ongoing R&D and clinical work require external capital until product revenue exists, if ever.

RAPT faces the typical risks of a clinical-stage biotech company: pipeline failure, long development timelines,...

high

Clinical development failure or delay

Drug candidates may not show sufficient safety or efficacy, or trials may take longer than planned.

Scope
Pipeline programs in inflammation, immunology, and oncology
Materiality
high
high

Funding and liquidity dependence

The company expects to need substantial additional capital before generating product revenue.

Scope
Equity, debt, collaborations, and strategic transactions
Materiality
high
medium

Commercialization capability gap

RAPT currently has no sales, marketing, or distribution infrastructure.

Scope
Future approved products
Materiality
high
medium

Reimbursement and pricing pressure

Payors may restrict coverage, require discounts, or demand additional evidence.

Scope
U.S. pharmaceutical commercialization
Materiality
high
medium

Competition and IP risk

Larger, better funded biotech and pharma companies may develop superior or earlier therapies.

Scope
Inflammation, immunology, and oncology markets
Materiality
high
medium

Supply chain and regulatory disruption

Clinical trials depend on CROs, manufacturers, and FDA/regulatory operations.

Scope
Trial sites, manufacturing, and approvals
Materiality
medium
Research and development expense recognition
Reported operating loss
Marketable securities and interest income
Other income, net
Prepaid R&D services
Timing of operating expenses
Future collaboration or licensing revenue
Potential future revenue recognition

Rapport Therapeutics, Inc.

RAPP · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Indaptus Therapeutics, Inc.

INDP · Pharmaceutical Preparations

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

: 29/04/2026